NOVARTIS FDA Approval NDA 021882

NDA 021882

NOVARTIS

FDA Drug Application

Application #021882

Documents

Letter2008-10-08
Letter2009-04-27
Letter2009-03-10
Letter2011-08-12
Letter2013-01-25
Letter2013-10-22
Letter2015-07-24
Label2007-04-25
Label2008-10-09
Label2009-04-28
Label2011-08-11
Label2013-06-04
Label2015-07-24
Review2006-01-10
Letter2005-11-08
Letter2007-05-01
Letter2008-01-09
Letter2010-02-05
Letter2011-04-13
Letter2012-09-18
Letter2013-01-25
Letter2013-05-31
Label2005-11-03
Label2008-01-08
Label2010-02-04
Label2011-04-11
Label2012-09-20
Label2013-01-24
Label2013-10-21
Letter2016-08-17
Label2016-08-12
Pediatric Medical Review1900-01-01
Pediatric Clinical Pharmacology Review1900-01-01
Pediatric Statistical Review1900-01-01
Label2018-02-22
Letter2018-02-23
Label2018-05-14
Letter2018-05-15
Label2018-12-14
Label2018-12-14
Letter2018-12-20
Letter2018-12-20
Label2019-05-29
Letter2019-06-04
Letter2019-07-29
Label2019-07-29
Medication Guide2019-07-29
Letter2020-07-24
Letter2020-07-27
Label2020-07-27
Medication Guide2020-07-27
Letter2023-01-17
Label2023-01-19

Application Sponsors

NDA 021882NOVARTIS

Marketing Status

Prescription001
Prescription002
Prescription003

Application Products

001TABLET, FOR SUSPENSION;ORAL125MG1EXJADEDEFERASIROX
002TABLET, FOR SUSPENSION;ORAL250MG1EXJADEDEFERASIROX
003TABLET, FOR SUSPENSION;ORAL500MG1EXJADEDEFERASIROX

FDA Submissions

TYPE 1; Type 1 - New Molecular EntityORIG1AP2005-11-02PRIORITY
LABELING; LabelingSUPPL2AP2007-04-20STANDARD
LABELING; LabelingSUPPL3AP2007-12-21STANDARD
LABELING; LabelingSUPPL4AP2008-10-02STANDARD
LABELING; LabelingSUPPL6AP2009-04-22STANDARD
LABELING; LabelingSUPPL7AP2009-03-05STANDARD
LABELING; LabelingSUPPL10AP2010-01-28UNKNOWN
LABELING; LabelingSUPPL11AP2011-04-11STANDARD
LABELING; LabelingSUPPL12AP2011-08-10STANDARD
LABELING; LabelingSUPPL14AP2012-09-14STANDARD
EFFICACY; EfficacySUPPL15AP2013-01-23STANDARD
LABELING; LabelingSUPPL16AP2013-01-23STANDARD
LABELING; LabelingSUPPL17AP2013-05-29STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL18AP2013-11-01PRIORITY
LABELING; LabelingSUPPL19AP2013-10-21STANDARD
LABELING; LabelingSUPPL21AP2015-07-23STANDARD
LABELING; LabelingSUPPL24AP2016-08-12STANDARD
EFFICACY; EfficacySUPPL25AP2018-05-11STANDARD
LABELING; LabelingSUPPL26AP2018-02-16STANDARD
EFFICACY; EfficacySUPPL28AP2018-12-12PRIORITY
LABELING; LabelingSUPPL29AP2018-12-12STANDARD
EFFICACY; EfficacySUPPL30AP2019-07-24STANDARD
EFFICACY; EfficacySUPPL31AP2019-05-24PRIORITY
EFFICACY; EfficacySUPPL33AP2020-07-23STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL37AP2023-01-17N/A

Submissions Property Types

ORIG1Null2
SUPPL10Null6
SUPPL11Null6
SUPPL12Null6
SUPPL14Null15
SUPPL15Null6
SUPPL16Null6
SUPPL17Null7
SUPPL18Null14
SUPPL19Orphan5
SUPPL21Null7
SUPPL24Null6
SUPPL25Null6
SUPPL26Null6
SUPPL28Orphan5
SUPPL29Null6
SUPPL30Null7
SUPPL31Null15
SUPPL33Null7

TE Codes

001PrescriptionAB
002PrescriptionAB
003PrescriptionAB

CDER Filings

cder:Array
(
    [0] => Array
        (
            [ApplNo] => 21882
            [companyName] => 
            [docInserts] => ["",""]
            [products] => []
            [labels] => 
            [originalApprovals] => []
            [supplements] => 
            [actionDate] => 0000-00-00
        )

)

© 2026 FDA.report
This site is not affiliated with or endorsed by the FDA.